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Summary 
Staphylococcus aureus commonly colonizes the epidermis, but it remains unclear how the 
host senses virulent but not commensal S. aureus to trigger skin inflammation. Using a model 
of epicutaneous S. aureus infection, we found that phenol-soluble modulin (PSM)D, a group 
of secreted peptides regulated via the S. aureus virulence quorum-sensing system, induces the 
release of keratinocyte (KC) IL-1D and IL-36D. IL-1R and IL-36R signaling was required for 
induction of IL-17, and Il17a-/-f-/- mice showed blunted S. aureus-induced inflammation. In 
mice with total or KC-specific deletion of Myd88, the adaptor that mediates IL-1R and IL-
36R signaling, the amounts of released IL-1D and IL-36D as well as IL-17 production by JGT 
cells and ILC3 and neutrophil infiltration were greatly reduced. Thus, KC Myd88 signaling 
plays a critical role in sensing S. aureus PSMDmediated.C damage which alert host 
immune cells to mount an IL-17-mediated skin inflammatory response to epicutaneous S. 
aureus infection.  
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Introduction 
The skin is the largest organ at the interface between the external environment and host 
tissues. The epidermis located on the skin surface is important in maintaining the physical 
and immunological barrier of the skin by protecting the host from harmful environmental 
stimuli including invasive microbes (Segre, 2006). Staphylococcus aureus, a Gram-positive 
bacterium, is a leading cause of human infection capable of invading most tissues of the 
human body. The superficial skin is a major infection site for S. aureus, which normally 
resides in 10-20% of healthy individuals (Lowy, 1998). The S. aureus causing skin infections 
often originate from resident bacteria that colonize the mucosal surfaces of the skin 
(Balasubramanian et al., 2017; Lowy, 1998). How S. aureus produces virulence factors to 
transform from a skin commensal to a pathogen is poorly understood. Previous studies 
suggested that this might be a consequence of activation of virulence gene regulatory 
networks in response to environmental signals (Novick and Geisinger, 2008). A major S. 
aureus virulence program is the accessory gene regulatory (Agr) quorum-sensing, a two-
component system that responds to bacterial density (Novick, 2003). Upon activation, the agr 
locus induces the expression of a wide array of secreted virulence factors including toxins 
and enzymes that are important for the adaptation of the pathogen to the environment 
(Novick, 2003). Agr-regulated toxins include phenol-soluble modulins (PSMs), a group of 
seven different peptides divided into α- and β-type PSMs (Cheung et al., 2014). PSM 
peptides form amphipathic α-helical structures capable of forming pores in artificial 
membranes (Wang et al., 2007). PSMD peptides are highly cytotoxic to a wide variety of 
cells including keratinocytes (KCs) while other PSMs have very limited cytotoxic activities 
(Nakamura et al., 2013; Wang et al., 2007). In a mouse epicutaneous model of S. aureus 
infection, G-toxin, a PSM peptide, promotes skin inflammation by inducing mast cell 
degranulation (Nakamura et al., 2013). However, the mechanism by which S. aureus interacts 
with KCs to trigger skin inflammation in vivo remains largely unknown.  
 
KCs are the predominant cell type in the stratified epithelial layer of the epidermis. In 
response to environmental stimuli, KCs produce a wide variety of molecules including 
multiple cytokines, chemokines and anti-microbial peptides (Kennedy-Crispin et al., 2012; 
Nestle et al., 2009). Some of these KC molecules, including IL-1D, high-mobility group box 
1 (HMGB1) protein and anti-microbial peptides, can be released upon tissue damage and 
function as ‘alarmins’ to activate the immune system (Rider et al., 2017; Yang et al., 2009). 
However, the role of KCs in S. aureus-induced inflammation in vivo is poorly understood 
because practically all cutaneous models of S. aureus infection rely on subepidermal 
inoculation or prior physical disruption of the epidermis (Miller et al., 2006; Wang et al., 
2007). In the intradermal or subcutaneous model of S. aureus infection, mice deficient in 
Myd88, the adaptor molecule that is critical for signaling through the Toll-like receptor 
(TLR)/IL-1/IL-18 family of receptors, showed increased inflammation, abscess formation 
and epidermal ulceration which correlated with impaired S. aureus clearance (Miller et al., 
2006). Furthermore, Il1r-/-, but not Tlr2-/-, mice showed increased inflammation and abscess 
formation in the subcutaneous infection model (Miller et al., 2006). However, the role of 
these signaling pathways in promoting inflammation after epidermal colonization of S. 
aureus remains unclear. Using conditions in which virulence genes are induced upon 
epidermal colonization, we show that S. aureus relies on virulent Agr-regulated 
PSMDpeptides to trigger cutaneous inflammation. PSMDinduces the release of IL-1D and 
IL-36 from KCs to orchestrate cutaneous inflammation via Myd88 signaling and IL-17 
production.  
  
Results  
Keratinocyte Myd88 is essential for S. aureus-induced skin inflammation 
We used a recently developed model of S. aureus colonization that induces Agr-regulated 
virulence to investigate the mechanism by which the pathogen triggers cutaneous 
inflammation (Nakamura et al., 2013). In this epicutaneous model, wild-type (WT) mice 
infected with S. aureus (strain LAC, pulsed-field type USA300) showed severe skin disease 
and inflammation characterized by neutrophil infiltrates and epidermal thickening on day 7 
after colonization (Figures 1A, 1B, 1D and 1E). In contrast, Myd88-/- mice showed little skin 
pathology when compared with WT mice (Figures 1A-1E). Unlike the epicutaneous model, 
Myd88-/- mice infected intradermally with S. aureus showed increased skin pathology and 
pathogen loads compared to that observed in WT-infected mice (Figures S1A-S1C), which is 
consistent with a previous report (Miller et al., 2006). In contrast, Myd88-/- mice exhibited 
lower S. aureus CFUs than WT mice in the epicutaneous model (Figure 1C), suggesting that 
Myd88-dependent inflammation promotes pathogen colonization in this model. Thus, the 
route of infection is critical to revealing the function of innate signaling pathways in host 
defense against S. aureus in the skin. To determine whether Myd88 acts within KCs, we 
crossed mice with a floxed exon of Myd88 (Myd88fl/fl mice) with a keratin 14 (K14)-Cre 
mouse deleter strain to generate K14-Cre-Myd88fl/fl mice with conditional deletion of Myd88 
within KCs. Notably, mice lacking Myd88 in KCs (Myd88∆ker) showed a phenotype similar to 
that observed in mice with whole-body deletion of Myd88 (Figures 1A, 1B and 1D). 
However, pathogen loads were comparable in Myd88∆ker mice and WT mice (Figure 1C). 
Furthermore, the reduction in epidermal thickening in Myd88∆ker mice was not as prominant 
as in Myd88-/- mice (Figure 1E). In contrast to the epicutaneous model, Myd88∆ker and WT 
mice showed comparable skin inflammation in response to intradermal S. aureus infection 
(Figures S1D-S1F). These results indicate a critical role for Myd88 and particularly Myd88 
in KCs for the induction of immune responses to S. aureus in the epicutaneous infection 
model.  
 
IL-1R and IL-36R are essential for induction of skin inflammation in epicutaneous S. 
aureus infection. 
Myd88 is a critical adaptor molecule required for signaling via multiple immune receptors, 
including TLR/IL-1R/IL-18R/IL-36R (Palomo et al., 2015; Takeuchi and Akira, 2002). 
Initial experiments showed that deficiency in TLR2, TLR4 or IL-18 did not affect either skin 
disease, histopathology or pathogen loads in the epicutanous model of S. aureus infection 
(Figures S2A and S2B). In contrast, mice deficient in IL-1R, which can be stimulated by 
either IL-1D or IL-1E exhibited a reduction in disease score, neutrophil infiltrates and 
epidermal thickening, despite similar pathogen loads when compared with WT mice (Figures 
2A-2E). Two  related cytokines IL-36α and IL-36γ are expressed in KCs (Gresnigt and van 
de Veerdonk, 2013) and activate the IL-36R that also signals via Myd88 (Towne et al., 2004). 
Administration of a neutralizing monoclonal antibody (Mab) against IL-36R also reduced 
neutrophil infiltration and epidermal thickening induced by epicutaneous S. aureus infection 
without affecting pathogen loads (Figures 2C-2E). Treatment of Ilr1-/- mice with the 
neutralizing anti-IL-36R Mab further reduced the disease score, neutrophil infiltration and 
epidermal thickening when compared WT mice (Figures 2A, 2B, 2D and 2E). These results 
indicate that both IL-1R and IL-36R signaling contribute to skin inflammation induced by S. 
aureus infection.  
 
S. aureus induces IL-1D and IL-36D expression via Myd88 in keratinocytes.  
Given that IL-1R signaling is important for S. aureus-induced inflammation, we asked 
whether IL-1D or IL-1E mediates skin pathology in the epicutaneous infection model. 
Infection with S. aureus showed comparable pathology, disease scores and pathogen loads in 
WT and Il1E-/- mice (Figure S2C). In contrast, neutralization of IL-1Dwith a Mab reduced 
skin pathology without affecting pathogen loads, compared with mice treated with isotype-
matched control Mab (Figures 3A-3C). Epicutaneous infection of S. aureus in WT mice 
substantially enhanced the expression of IL-1D and IL-36D in the upper area of the epidermis, 
which was reduced in Myd88∆ker and Myd88-/- mice (Figures 3D and S3). Consistent with 
results showed in Figure 1C, pathogen loads were reduced in the skin of Myd88-/- mice 
compared to WT and Myd88∆ker (Figure 3E). To determine whether S. aureus produces 
molecules that induce IL-1D and IL-36D release from KCs, primary KCs from WT and 
Myd88-/- mice were cultured under conditions that promote their terminal differentiation 
(Bikle et al., 2012) and then incubated with supernatants of S. aureus cultures. There was 
marked release of IL-1D and IL-36D after 60 min incubation of WT KCs with S. aureus 
culture supernatants (Figures 3F and 3G). Notably, the release of IL-1D and IL-36D was 
reduced in KCs from Myd88-/- mice (Figures 3F and 3G). Furthermore, the KC release of 
IL-1D was markedly reduced and that of IL-36D was partially affected in KC deficient in IL-
1R (Figures 3H and 3I), suggesting that IL-1D release enhances IL-1D and IL-
36Dproduction via IL-1R signaling in KCs. In addition, IL-36Drelease by S. aureus was 
inhibited by neutralization of IL-36R whereas that of IL-1Dwas only minimally affected 
(Figures 3J and 3K). Collectively these results indicate that IL-1D and IL36D production are 
regulated by S. aureus stimulation via Myd88 signaling in KCs. 
 
IL-17 is critical for S. aureus-induced skin inflammation  
Members of the IL-1 family of cytokines are important for the induction of cellular immune 
responses and production of several cytokines including IL-17 and IL-22 (Sonnenberg et al., 
2011; Villarino and Laurence, 2015). To determine which cytokines are induced upon 
epicutaneous infection with S. aureus, we assessed the production of multiple cytokines by 
skin immune cells at the peak of inflammation. Total skin cells were gated on hematopoietic 
CD45+CD90+ cells and the number of CD45+CD90+ cells producing IL-17A, IL-17F, IL-22, 
interferon-J (IFN-J) and GM-CSF was measured by flow cytometry. The analysis revealed 
that epicutaneous S. aureus infection induces a marked increase in the number of IL-17A-
producing cells and a modest increase in cells producing IL-17F and IL-22 while there was 
minimal or no induction of IFN-Jand GM-CSF-producing cells (Figure 4A). The number of 
leukocytes infiltrating the skin including IL-17A-producing cells, was reduced in Myd88-/- 
mice (Figure 4B). Furthermore, the production of IL17A was reduced in the skin of 
Myd88∆ker and Il1r-/- mice injected with IL-36R neutralizing Mab (Figure 4C). The 
production of IL-17F was also reduced in Il1r-/- mice injected with IL-36R neutralizing Mab 
compared to WT mice (Figure 4C). To determine if IL-17 was important for the induction of 
skin inflammation, WT mice and mice doubly deficient in IL-17A and IL-17F were infected 
epicutaneously with S. aureus. We found that Il17a-/-f-/- mice exhibited greatly reduced skin 
disease scores and neutrophil infiltration, but normal pathogen loads, compared with WT 
mice (Figures 4D-4H). In contrast, WT and Il22-/- mice showed comparable skin phenotype 
after S. aureus infection (Figure S2D). These results indicate that S. aureus induces IL-17 via 
Myd88 signaling which is critical for inflammatory pathology in the skin. 
 
JGT cells and type 3 innate lymphoid cells are the main producers of IL-17 in response 
to skin infection.   
We next asked which immune cell population(s) produces IL-17 in response to epicutaneous 
S. aureus infection. Gating on CD45+ cells revealed two populations of IL-17+CD90+ cells in 
the skin of mice epicutaneouly infected with S. aureus (Figure 5A). These included 
JGintermediate dermal JGT cells and lineage-negative CD45+CD90+ immune cells which marks 
type 3 innate lymphoid cells (ILC3) (Figure 5A). To determine whether JGT cells contribute 
to skin inflammation in response to S. aureus, we infected WT and TcrG-/- mice with the 
pathogen and assessed the pathology and disease scores in the skin. We found comparable 
disease scores, but reduced neutrophil infiltration in TcrG-/- mice compared with WT mice 
(Figures 5B-5F). As expected, IL-17-producing JGT cells were absent in the skin of infected 
TcrG-/- mice, but the population of IL-17-producing ILC was unchanged in TcrG-/- mice 
(Figure 5G). To determine whether ILC3 contribute to skin inflammation, we treated TcrG-/- 
mice with anti-CD90 Mab to deplete the ILC3populationFigure S4and infected the 
treated mice epicutaneously with S. aureus. Treatment with anti-CD90 Mab significantly 
reduced skin disease scores without affecting pathogen loads in TcrG-/- mice when compared 
with mutant mice treated with control Mab (Figures 5H-5J). These results indicate that both 
ILC3 and JGT cells contribute to skin inflammation in response to epicutaneous S. aureus 
infection.  
 
S. aureus PSMDinduceskeratinocyteIL-1D and IL-36D release to mediate skin 
inflammation  
We next assessed which factor(s) released by S. aureus is important for eliciting the release 
of IL-1D and IL-36D from KCs and thereby triggering IL-17-dependent skin inflammation. 
PSMs including the peptides PSMα1 through PSMα4 induce robust cell death of mouse KCs 
in vitro (Nakamura et al., 2013). Because the Agr virulence system that controls the 
production of PSMD is activated during epicutaneous S. aureus infection in our model 
(Nakamura et al., 2013), we asked whether PSMD is important for eliciting skin 
inflammation. We first assessed whether PSMD is important for the release of IL-1D and IL-
36D by incubating primary mouse KCs with culture supernatants from WT or isogenic S. 
aureus mutant strains deficient in PSMDpsmDorPSMEpsmE. Incubation with 
the culture supernatant from WT and mutant psmE, but not mutant psmD, strain induced cell 
death and release of IL-1D and IL-36D (Figures 6A-6C, S5A-S5B). In addition to mouse 
KCs, human KCs showed a marked release of IL-1Dand enhanced cytotoxicity after 
treatment with supernatants from the WT and mutant psmEstrains, but not mutant psmD 
(Figures S6A-S6B). Complementation of mutant 'psmD S. aureus with psmD plasmid 
restored cytotoxicity and cytokine release in both mouse and human KCs (Figures S5F-S5G, 
S6C-S6D). In addition, stimulation of human KCs with synthetic PSMD3 peptide induced IL-
1D release and cytotoxicity (Figures S6E-S6F). Furthermore, pre-treatment with anakinra, an 
IL-1R antagonist, reduced IL-1Drelease induced by PSMD3 peptide without affecting 
cytotoxicity (Figures S6G-S6H). To determine whether PSMD is important for the induction 
of skin inflammation, we infected WT mice with WT and mutant psmD and psmE S. aureus 
strains using the epicutaneous model. Histological analysis revealed that the ability of the 
psmDmutant strain to induce skin disease, epidermal thickening and neutrophil infiltration 
were impaired compared with the WT and psmE strains (Figures 6D, 6E, 6G, 6H, S5C and 
S5D). There were reduced pathogen loads and IL-17 production in the skin of mice infected 
with the psmD mutant strain when compared to the WT bacterium (Figures 6F, 6I, and S5E). 
These results suggest that PSMD from S. aureus is a key virulence factor for triggering S. 
aureus-induced skin inflammation.  
Discussion  
The mechanism by which S. aureus triggers skin inflammation in response to epidermal 
colonization has remained largely unknown. The paucity of knowledge is largely explained 
by the lack of a model of epidermal infection that mimics the virulent lifestyle of the 
pathogen. Using conditions in which S. aureus colonizes the epidermis and induces virulence 
(Nakamura et al., 2013), we found that Agr-regulated PSMD peptides trigger the release the 
KC alarmins IL-1D and IL-36D to elicit skin inflammation. These observations indicate that 
the host senses the pathogen indirectly through the induction of KC damage triggered by 
cytotoxic virulence factors. Because expression of aggressive, cytolytic PSMs appears to be 
limited mostly to S. aureus in comparison to S. epidermidis (Cheung et al., 2010), these 
observations suggest a model in which the host immune system can discriminate a virulent 
pathogen from commensals by sensing KC damage. Because PSMD peptides have been 
shown to induce chemokines from neutrophils (Kretschmer et al., 2010; Wang et al., 2007), it 
is possible that PSMD also contribute to skin inflammation via KC-independent mechanisms. 
Previous work showed that epidermal colonization of some commensals can induce IL-17-
producing CD8+ cells in the dermis (Naik et al., 2015; Naik et al., 2012). However, 
colonization by commensals does not trigger overt inflammation and skin pathology 
including epidermal thickening and neutrophil recruitment which is observed after S. aureus 
infection (Naik et al., 2015). This model also implies that the host senses not the bacterium 
per se, but the virulent state of the pathogen through PSMD-induced release of KC alarmins. 
S. aureus lacking PSMD peptides accumulate at lower numbers than the WT bacterium after 
epicutaneous colonization. These results suggest that the pathogen benefits from PSMD 
production, at least in part, by inducing the release of nutrients or other factors from damaged 
KCs.  
These studies have revealed a critical role for Myd88 signaling within KCs in orchestrating 
cutaneous inflammation induced by epicutaneous S. aureus infection. In mice with deletion 
of Myd88 in KCs, there was reduction of skin inflammation which was associated with 
impaired production of IL-1Dand IL-36D by KCs. Studies in vivo and in vitro revealed that 
IL-1D and IL-36D expression is enhanced by S. aureus stimulation and this is impaired in 
Myd88-/- KCs. Furthermore, induction of IL-1D and IL-36D by S. aureus was reduced by IL-
1R defiency and IL-36R neutralization, respectively. These results suggest that IL-1D and IL-
36D act in a positive feedback loop that regulates their own expression via Myd88 signaling 
in KCs. These studies do not rule out a role for Myd88 on cells other than KCs to regulate the 
inflammatory response in the skin. IL-1R and IL-36R are expressed on immune cells and 
regulate the differentiation of IL-17-producing immune cells including JGT cells, Th17 cells 
and ILC3 (Klose and Artis, 2016; Tortola et al., 2012; Vigne et al., 2011). Therefore, it is 
likely that Myd88 also acts critically on immune cells via IL-1R and IL-36R stimulation to 
regulate the induction of IL-17-producing cells in response to S. aureus epidermal infection. 
The phenotype of Myd88-/- mice is in contrast to that observed in the intradermal S. aureus 
inoculation model in which Myd88 deficiency is associated with increased pathogen loads 
and tissue pathology (Miller et al., 2006). The opposite roles of Myd88 in the two models 
suggest a different function of the immune system in the presence and absence of pathogen 
invasion. In the epicutaneous model, the epidermal barrier is not physically breached, and 
epidermal thickening and the recruitment of neutrophils are induced via Myd88 function to 
prevent pathogen invasion. In contrast to the role of Myd88 signaling in sensing pathogen on 
the epidermal surface in the epicutaneous model, in the dermal/subcutaneous model Myd88 
signaling appears more critical in promoting killing of S. aureus by immune cells within in 
the dermis and subcutaneous tissues (Miller et al., 2006).  
 
Our findings may have relevance to the inflammatory response associated with some forms 
of dermatitis in humans. Over 90% of atopic dermatitis (AD) patients are colonized in the 
lesional epidermis by S. aureus, which is increased during disease flares (Kong et al., 2012; 
Rudikoff and Lebwohl, 1998). In adult AD, lesional skin has been associated with Th2, Th22 
and Th17 immune polarization, but strong Th17 polarization is characteristic of new-onset 
pediatric AD (Esaki et al., 2016). Previous work revealed the expression of S. aureus Agr 
virulence factors that produce PSMs in the lesional skin in AD (Nakamura et al., 2013). 
Furthermore, G-toxin promoted allergic skin disease through the activation of mast cells that 
induces Th2 type inflammation in the epicutaneous S. aureus model (Nakamura et al., 2013). 
Together, these results indicate that different PSMs contribute to S. aureus-induced skin IL-
17-driven inflammation via different mechanisms. However, a role for PSMD-induced IL-1D 
and IL-36 production in the pathogenesis of AD remains to be investigated. Although there is 
no direct evidence of S. aureus colonization in psoriasis, both psoriasis vulgaris and 
generalized pustular psoriasis are associated with increased production of IL-1 and IL-36 
cytokines (D'Erme et al., 2015; Johnston et al., 2016). The importance of IL-36 in 
generalized pustular psoriasis is highlighted by the observation that missense loss-of-function 
mutations of the IL-36R antagonist leading to unrestrained IL-36 activity, which is associated 
with the disease (Marrakchi et al., 2011). Furthermore, neutralization of IL-17 is highly 
effective in the treatment of psoriasis (McInnes et al., 2015; Papp et al., 2012). Thus, IL-17 
appears to promote protective immunity against pathogens, but if its production is excessive 
can also contribute to inflammatory disease. Our observations suggest that identifying 
pathogenic stimuli that trigger KC damage would help unravel the mechanisms underlying 
the induction of pathogenic IL-17 responses often associated with psoriasis.  
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Figure Legends 
Figure 1. Keratinocyte Myd88 is important for epicutaneous S. aureus-induced skin 
inflammation. A, C57BL/6 (WT), K14-CreMyd88fl/fl (Myd88∆ker) and Myd88-/- mice were 
epicutaneously colonized with S. aureus. WT mice treated with PBS are shown for 
comparison. Representative macroscopic images and hematoxylin and eosin (HE)-stained 
skin sections 7 days after colonization (n=3 to 7 mice per group). Scale bars, 100 µm. B, Day 
7 skin disease scores of WT, Myd88∆ker and Myd88-/- mice colonized with S. aureus. C-E, 
The number of S. aureus colony forming unit (CFU) (C), numbers of neutrophils per high 
power field (D), and epidermal thickness (E) in the skin of WT, Myd88∆ker and Myd88-/- mice 
7 days after colonization with S. aureus. Each dot represents a mouse (B, C). Data are 
presented as mean ± SD (D, E). Results shown represent combined data of 2 independent 
experiments. ND; not detected, n.s.; not significant, *P<0.05; **P<0.01, by Kruskal-Wallis 
test. 
 
Figure 2. Both IL-1R and IL-36R contribute to skin inflammation induced by 
epicutaneous S. aureus colonization. A, WT, Il1r-/-, WT mice treated with IL-36R blocking 
antibody (IL-36RAb), and Il1r-/- mice treated with IL-36RAb were epicutaneously colonized 
with S. aureus for 7 days. Representative macroscopic images and HE-stained skin sections 
of mice colonized with S. aureus or treated with PBS (n=4 to 8 mice per group). Scale bars, 
100 µm. B-E, Day 7 skin disease scores (B), S. aureus CFU in the skin (C), the number of 
neutrophils in the skin (D) and epidermal thickness (E) of WT, Il1r-/-, WT mice treated with 
IL-36RAb, and Il1r-/- mice treated with IL-36RAb (n=4 to 8 mice per group). WT mice 
treated with PBS are shown for comparison. Each dot represents a mouse (B, C). Data are 
presented as mean ± SD (D, E). Data represent combined results from 3 independent 
experiments. ND; not detected, n.s.; not significant, *P<0.05 and **P<0.01, by Kruskal-
Wallis test (B, C) or by one-way ANOVA test with Bonferroni’s correction (D, E).  
 
Figure 3. IL-1D and IL-36D are induced by S. aureus via Myd88 signaling in 
keratinocytes. A, WT mice treated with IL-1D blocking antibody (IL-1DAb) or isotype-
matched control Ab were epicutaneously colonized with S. aureus. Representative 
macroscopic images of mice colonized with S. aureus (n=5 mice per group). B-C, Skin 
disease scores (B) and S. aureus CFU in the skin (C) of WT mice treated with IL-1D Ab or 
control Ab. Each dot represents a mouse. D, Skin tissues of WT, and Myd88∆ker and Myd88-/- 
mice colonized with S. aureus or treated with PBS were stained with Hoechst stain (blue) and 
antibody against IL-1D (red) or Hoechst stain (blue) and antibodies against S. aureus (red) 
and IL-36D (green). Scale bars, 50 µm. E, The numbers of S. aureus per high power field are 
(HPF) are shown. Each dot represents average results from an individual mouse. Data are 
representative of 2 independent experiments. F-K, IL-1D (F, H, J) and IL-36D(G, I, K) 
release of differentiated primary KCs isolated from WT and Myd88-/- mice (F, G), WT and 
Ilr1-/- mice (H, I), or WT mice in the presence of anti-IL-36 neutralizing Mab or isotype-
matched control Mab (J, K) and stimulated with culture supernatants of S. aureus for 
indicated time. IL-1D and IL-36D were detected by ELISA assay and immunoblotting, 
respectively. E-actin in whole cell lysates is shown as loading control. Data are presented as 
mean±SD. Data are presented as mean ± SD. Data are representative of at least 2 independent 
experiments. ND; not detected, n.s.; not significant, *P<0.05 and **P<0.01, by unpaired two-
tailed Mann-Whitney U test (B, C, F, H, J) or Kruskal-Wallis test (E).  
 
Figure 4. IL-17 is critical for skin inflammation induced by epicutaneous S. aureus 
colonization. A, Production of IL-17A, IL-17F, IL-22, IFN-J and GM-CSF by skin cells 
isolated from WT mice colonized with S. aureus or treated with PBS. Intracellular cytokine 
production was assessed in gated CD45+CD90+ cells on day 7 after pathogen colonization by 
flow cytometry. Representative flow cytometry profiles (left panels) and the number of 
cytokine-producing cells (right panel). Results in right panel represent mean ± SD of 2 
experiments. B, Production of IL-17A by CD45+ cells in the skin of WT and Myd88-/- mice 7 
days after epicutaneous infection. Representative flow cytometry profiles (left panels) and the 
number of IL-17A-producing cells (right panel). Results in right panel represent mean ± SD 
of 2 experiments. C, IL-17A and IL-17F production in skin tissues of WT mice, Myd88∆ker 
mice, Il1r-/- mice, WT mice treated with IL-36RAb and Il1r-/- mice treated with IL-36RAb 7 
days after pathogen colonization. WT mice treated with PBS are shown for comparison. Each 
dot represents a mouse. Data represent combined data of 3 independent experiments. D WT 
and Il17a-/-f-/- mice were epicutaneously colonized with S. aureus or treated with PBS. 
Representative macroscopic images and HE-stained skin sections 7 days after colonization 
(n=7 mice per group). Scale bars, 100 µm. E-H, Skin disease scores (E), S. aureus CFU in 
the skin (F), the numbers of neutrophils (G) and epidermal thickness (H) of WT and Il17a-/-f-
/- mice colonized with S. aureus. WT mice treated with PBS are shown for comparison. Each 
dot represents a mouse (C, E, F). Data are presented as mean ± SD (A, B, G, H). Results 
shown represent combined data of 3 independent experiments. ND; not detected, n.s.; not 
significant, *P<0.05; **P<0.01, by unpaired two-tailed Mann-Whitney U test (A, B, E, F, G, 
H) or Kruskal-Wallis test (C). 
 
Figure 5. Both JG T cells and ILC3 contribute to skin inflammation after S. aureus 
colonization. A, IL-17A-producing JG T cells, ILC3 and DE T cells were evaluated by flow 
cytometric analysis after epicutaneous S. aureus colonization. Flow cytometric analysis of 
lineage (B220, CD11b, CD11c, Gr-1, NK1.1)-negative cells and JG T cells was performed on 
gated CD45+CD90+IL-17A+ skin cells. Data are representative of 3 independent experiments. 
B, WT and TcrG-/- mice were epicutaneously colonized with S. aureus. WT mice treated with 
PBS are shown for comparison. Representative macroscopic images and HE-stained sections 
of mouse skin on day 7 after colonization (n=10 to 15 mice per group). Scale bars, 100 µm. 
C-E, Day 7 skin disease scores (C), S. aureus CFU in the skin (D), neutrophil numbers in the 
skin (E) and epidermal thickening (F) of WT and TcrG-/- mice colonized with S. aureus. Each 
dot represents a mouse (C, D). Data are presented as mean ± SD (E, F). Results represent 
combined data of 4 independent experiments. G, IL-17A-producing JG T cells and ILC3 were 
evaluated by flow cytometric analysis in WT and TcrG-/- mice after S. aureus colonization. 
Representative flow cytometric profiles of CD3 and lineage labeling on CD45+CD90+IL-
17A+ skin cells (left panels). The number of IL-17A+ JG T cells and ILC3 in WT and TcrG-/- 
mice (right panels). Results on right panels represent mean ± SD of 3 experiments. H, WT 
mice and TcrG-/- mice treated with control Ab and anti-CD90 Ab were epicutaneously 
colonized with S. aureus. Representative macroscopic images and HE-stained sections of 
mouse skin on day 7 after colonization (n=7 mice per group). Scale bars, 100 µm. I-J, Skin 
disease scores (I) and S. aureus CFU in the skin (J) of WT mice and TcrG-/- mice treated with 
control Ab and anti-CD90 Ab. Each dot represents a mouse. Results represent combined data 
of 2 independent experiments. ND; not detected, n.s.; not significant, *P<0.05 and **P<0.01, 
by using unpaired two-tailed Mann-Whitney U test (C-G) or by one-way ANOVA test with 
Bonferroni’s correction (I, J). 
 
Figure 6. PSMD peptides induce the release of keratinocyte IL-1D and IL-36D to 
mediate skin inflammation. A-B, IL-1D release (A) and cytotoxicity (B) of primary KCs 
from WT mice stimulated with culture supernatant of WT and 'psma S. aureus (LAC strain) 
for indicated time. Data are presented as mean ± SD. C, IL-36D release from primary KCs 
stimulated with culture supernatant of WT or 'psma S. aureus for indicated time. IL-36D was 
detected by immunoblotting. E-actin in whole cell lysates is shown as loading control. D, 
Representative macroscopic images (top panels) and HE-stained sections (middle upper 
panels), and sections stained with Hoechst stain (blue) and antibody against IL-1D (red) 
(middle lower panels) and stained with Hoechst stain (blue) and antibodies against S. aureus 
(red) and IL-36D (green) (bottom panels) of the skin from WT mice colonized with WT and 
'psma S. aureus or treated with PBS (n=5 to 8 per group) 7 days post infection. 
Epidermis/dermis border is marked by dotted white line. Scale bars, 100 µm (middle upper 
panels), 50 µm (middle lower panels) and 25 µm (bottom panels). E-H, Day 7 skin disease 
scores (E), S. aureus CFU in the skin (F), quantification of neutrophils in the lesional skin 
(G) and epidermal thickening (H) of WT mice colonized with WT and 'psma S. aureus or 
treated with PBS (n=5 to 8 per group). Each dot represents a mouse (E, F, I). Data are 
presented as mean ± SD (G, H). I, The amounts of IL-17A and IL-17F in the lesional skin of 
WT mice colonized with WT or 'psma S. aureus or WT mice treated with PBS for 7 days. 
Each dot represents a mouse. Results represent combined data of 3 independent experiments. 
Data are representative of at least 2 independent experiments. ND; not detected, n.s.; not 
significant, *P<0.05 and **P<0.01, by unpaired, two-tailed Mann-Whitney U test. 
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CONTACT FOR REAGENT AND RESOURCING SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Yuumi Nakamura (yumi01@chiba-u.jp). 
 
EXPERIMENTAL MODELS AND SUBJECTS DETAILS 
 
Animals 
C57BL/6 mice were purchased from CLEA Co. (Tokyo, Japan) or the Jackson Laboratory 
and expanded in our mouse Facility. K14-Cre and TcrG were purchased from the Jackson 
Laboratory. Tlr2-/-4-/-, Myd88-/-, Il1r-/-, Il1E-/-, Il18-/- and Il17a-/-f-/- mice on C57BL/6 
background have been described previously (Adachi et al., 1998; Franchi et al., 2012; Horai 
et al., 1998; Hoshino et al., 1999; Ishigame et al., 2009; Takeda et al., 1998; Takeuchi et al., 
1999). Myd88fl/fl mice on C57BL/6 background were a gift from Dr. Xiaoxia Li (the 
Cleveland Clinic). Il22-/- mice on C57BL/6 background were obtained from Genentech. All 
mice were maintained under specific pathogen-free conditions and were used at 8 to 12 
weeks of age. All animal studies were performed according to approved protocols by Chiba 
University or the University of Michigan Review Board for Animal Care. 
 
Isolation of murine primary keratinocytes 
Skins isolated from neonatal (day 1-3 after birth) WT, Il1r-/- and Myd88-/- mice were treated 
with 5 mg/ml dispase (CELLnTEC) overnight and then separated into dermis and epidermis. 
The epidermis sheets were treated with accutase (CELLnTEC) for 30 min and single-cell 
suspensions prepared from the epidermal sheets were cultured in CnT-07 medium 
(CELLnTEC) for 5-6 days. After confluency, terminal differentiation of KCs was induced by 
addition of 1.2 mM CaCl2 for the last 2 days. To block IL-36R, mouse KCs were treated with 
anti-IL-36R Ab (30 Pg/ml) or its isotype control Ab (clone: 2A3)(BioXCell) before addition 
of CaCl2. 
 
Preparation of human primary keratinocytes  
Human primary KCs were established as previously described (Nakano et al., 2016). 1x104 
cells in 24-well plate were cultured in Keratinocyte Growth Medium 2 (PromoCell) for 4-7 
days. After confluency, terminal differentiation of KCs was induced by an addition of 1.8 
mM CaCl2 for last 2 days. To block human IL-1 receptor, human primary KCs were treated 
with human IL-1 receptor antagonist, Anakinra (50 Pg/ml) (Wako), every 12 hrs from 48 hrs 
before stimulation. The collection of skin samples and the use of primary KC samples was 
approved by the ethics committee of Chiba University Graduate School of Medicine (No. 
519). 
 
METHOD DETAILS 
 
Antibody treatment 
For antibody-mediated depletion, antibodies were purchased from BioXCell. To deplete 
ILCs, mice were treated with anti-CD90 antibody (200 Pg) (clone: T24/31) subcutaneously 
on day -4, -2, 0, 2, 4, and 6 of S. aureus infection. Mice were treated with anti-IL-1D 
antibody (100 Pg) (clone: ALF-161) subcutaneously on a daily base starting from day -1 of 
infection. To neutralize IL-36R, mice were injected intradermally on day 0 and 
intraperitoneally on day 1, 3 and 5 with an anti-IL36R Mab (50 Pg) (clone: M616) provided 
by Amgen.  
 
Cell isolation and flow cytometric analysis  
For isolation of skin mononuclear cells, skin tissues were treated with 0.5% dispase II 
(Sigma) and then digested with 1.6 mg/ml collagenase type 2 (Worthington), 100 Pg/ml 
deoxyribonuclease I (DNase I; Sigma) and 1.2 mg/ml hyaruronidase (Sigma). The cells were 
resuspended on a Percoll gradient (75%/40%) (GE Healthcare) and centrifuged at 2000 rpm 
for 20 min at 25°C. Single-cell suspensions were stimulated with 100 ng/ml phorbol 12-
myristate 13-acetate (PMA; Sigma) plus 1 PM ionomycin  (Sigma) for 4 hrs in the presence 
of brefeldin A (BD Biosciences) and then stained with the following fluorochrome-
conjugated antibodies purchased from BD Biosciences, Biolegend, or eBioscience: 
Allophycocyanin (APC)-conjugated anti-CD45 (30-F11); brilliant violet 421-conjugated anti-
CD3H (145-2C11) and anti-JG TCR (GL3); Fixable Viability Dye eFluor 780; fluorescein 
isothiocyanate (FITC)-conjugated anti-CD90.2 (53-2.1); pacific blue-conjugated anti-CD90.2 
(53-2.1); peridinin chlorophyll protein complex-cyanin 5.5 (PerCP5.5)-conjugated Armenian 
Hamster IgG (HTK888), anti-CD45 (30-F11) and anti-TCRE (H57-597); phycoerythrin (PE)-
conjugated anti-B220 (RA-6B2), anti-CD11b (M1/70), anti-CD11c (HL3), anti-JG TCR 
(GL3), anti-Gr1 (RB6-8C5) and anti-NK1.1 (PK136) ; PE-Cy7 conjugated anti-CD45 (30-
F11). The cells were fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences) 
before intracellular staining with APC-conjugated anti-IL-17A (TC11-18H10), FITC-
conjugated anti-GM-CSF (MP1-22E9), PerCP-eFluor710-conjugated anti-IL-22 (1H8PWSR) 
and PE-conjugated anti-IFN-J (XMG1.2) and anti-IL-17F (eBio18F10) and then analyzed on 
a LSRII flow cytometer (BD Biosciences). 
 
Cytometric bead assay 
Supernatants from crude suspension of epidermis and dermis were collected from colonized 
skin and then protein level of IL-17A and IL-17F was measured by BDTM CBA Flex Sets 
according to the manufacturer’s instructions (BD Biosciences). The results were generated 
using CBA analysis software (BD Bioscience-PharMingen). 
 Cytotoxicity Assay 
Cytotoxicity were measured by LDH release assay with CytoTox 96® Non-Radioactive 
Cytotoxicity Assay (Promega). Primary KCs were stimulated with various S. aureus culture 
supernatants and LDH release assay was performed according to manufacturers’ instructions. 
 
Enzyme-linked immunosorbent assay 
Mouse IL-1D was detected with IL-1 alpha ELISA Ready-Set-Go! Kit (eBioscience). 
Purified IL-1D capturing antibody was added to a coated Nunc-ImmunoTM plate (Thermo 
scientific). After blocking with blocking buffer provided in the kit, supernatants from primary 
KCs were added and the cells were incubated at room temperature for 2 h. The binding of IL-
1D was detected by HRP-conjugated detection antibody and TMB solution (eBioscience). 
Human IL-1D was detected with Quantikine® ELISA Human IL-1D/IL-1F1 Immunoassay 
(R&D). IL-1D measurement was performed according to manufacturers’ instructions. 
 
Western blotting 
Supernatants were concentrated with an Amicon® Ultra-0.5 centrifuge filter device. Primary 
KCs were lysed in the presence of proteinase-inhibitor (Thermo Scientific) and RIPA buffer 
(Wako) was added. The eluted samples were separated on 15% SDS-PAGE, transferred to 
polyvinyldifluoride membranes by electorophoresis and then analyzed by immunoblot with 
anti-mouse IL-36D antibody (R&D systems) followed by HRP-conjugated secondary 
antibody. 
 
Immunofluorescent staining 
Sections of skins fixed in 10% paraformaldehyde were treated with Target Retrieval Solution 
pH 9 (Dako) for IL-36D immunofluorescent staining, and frozen sections of skins were fixed 
with aceton for IL-1D immunofluorescent staining. The skin sections were treated with 
polyclonal antibodies against mouse IL-36D (R&D systems) and S. aureus (abcam) at 4˚C 
overnight and then stained with Alexa Fluor 488-labeled anti-goat IgG antibodies (Life 
technologies) and Alexa Fluor 647 anti-mouse IgG antibodies (Invitrogen), respectively. For 
IL-1D and nuclear staining, PE-conjugated anti-IL-1D (ALF-161, Biolegend) and Hoechst 
(Invitrogen) were used, respectively. Images of stained sections were viewed with 
fluorescence microscope Axio Observer (Carl Zeiss) for IL-36D and BZ-X700 (Keyence) for 
IL-1D.  
 
S. aureus colonization 
The methicillin-resistant Staphylococcus aureus strain USA300 (LAC) and the isogenic 
'psma, 'psmDpTXΔ16, 'psmDpTXΔD and 'psmE mutant strains have been described 
(Wang et al., 2007). For colonization, bacteria were grown for 4 hrs in tryptic soy broth with 
shaking at 37˚C. Mice were colonized on the shaved dorsal skin of mice by applying a 1 cm2 
sterile gauze containing 1 x 108 CFUs of S. aureus which was covered with occlusive plastic 
dressing. In some experiments, mice were intradermally injected with 1 x 106 CFUs of S. 
aureus. To determine bacterial numbers in the colonized skin, skin was collected from 
individual mice, homogenized in cold PBS and plated at serial dilution onto Mannitol-salt 
agar containing 10% egg yolk. The number of CFU was determined after 24 hrs of incubation 
at 37˚C. Mice were sacrificed on day 7 day after colonization, and skins were assessed in a 
blinded fashion using a scoring system described previously (Nakamura et al., 2013). Briefly, 
4 points were used to denote the severity of erythema (0, none; 1, mild; 2, moderate; 3, 
severe), scaling (0, none; 1, mild; 2, moderate; 3, severe), erosion (0, none; 1, mild; 2, 
moderate; 3, severe), edema (0, none; 1, mild; 2, moderate; 3, severe), and thickness (0, none; 
1, mild; 2, moderate; 3, severe). Skin samples were fixed in 10% formalin and processed for 
HE staining or frozen sections were obtained for immunohistochemistry. 
  
 
QUANTIFICATION AND STATISTICAL ANALYSES 
Statistical analyses were performed using GraphPad Prism software version 5.0 (GraphPad 
Software Inc.). Differences between two groups were evaluated using Student’s t test 
(parametric) or Mann-Whitney U test (non-parametric). For multiple comparisons, statistical 
analysis was performed using one-way ANOVA (parametric) or Kruscal-Wallis test (non-
parametric), and then Bonferroni test for parametric samples, or Dunn’s test for non-
parametric samples as a post-hoc test. Differences at P<0.05 were considered significant.  
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Figure S1. Myd88-/- mice show increased skin lesions and pathogen loads after 
intradermal S. aureus infection. Related to Figure 1.
A, WT and Myd88-/- mice were intradermally inoculated with S. aureus. Representative 
macroscopic images of mice colonized with S. aureus 7 days after infection (n=4 mice per 
group). B-C, Skin lesion size (B) of indicated time point. S. aureus CFU in the skin (C) of WT 
and Myd88-/- mice 7 days after infection. D, WT and Myd88∆ker mice were intradermally
inoculated with S. aureus. Representative macroscopic images of mice colonized with S. 
aureus 7 days after infection (n=4 to 7 mice per group). E-F, Skin lesion size (E) at indicated 
time point. S. aureus CFU in the skin (F) of WT and Myd88∆ker mice 7 days after infection. 
Data are presented as mean ± SD. Data are representative of 2 independent experiments. 
n.s.; not significant, *P<0.05 and **P<0.01, by unpaired two-tailed Mann-Whitney U test.
Tlr2-/-4-/-
A
WT
Figure S2
B
Il18-/-WT
C
Il1b-/-WT
WT
D
Il22-/-
Figure S2. TLR 2/4, IL-1b, IL-18 and IL-22 are dispensable for S. aureus-induced skin 
inflammation. Related to Figure 2-4.
A-D, WT, Tlr2-/-4-/- (A), Il18-/- (B), Il1b-/- (C) and Il22-/- mice (D) were epicutaneously colonized 
with S. aureus. Representative macroscopic images, skin disease scores and S. aureus CFU 
in the skin of the mice colonized with S. aureus (n=4 to 11 mice per group). Each dot 
represents a mouse. Data are representative of at least 2 independent experiments. ND; not 
detected, n.s.; not significant, by unpaired two-tailed Mann-Whitney U test. 
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Figure S3. Expression of IL-1a and IL-36a in the skin of WT, Myd88∆ker and Myd88-/-
mice infected epicutaneously with S. aureus. Related to Figure 3.
Representative slides from the skin of 3 different mice stained with Hoechst stain (blue) and 
antibodies against S. aureus (red) and IL-36a (green) (A) or Hoechst stain (blue) and antibody 
against IL-1a (red)(B). WT, Myd88∆ker and Myd88-/- mice colonized with S. aureus (LAC WT), 
WT mice with Dpsma S. aureus (LAC Dpsma) and WT mice treated with PBS are shown. 
Data are representative of at least 2 independent experiments. Scale bars, 50 µm.
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Figure S4. Administration of anti-CD90 Ab depletes IL-17 producers in Tcrd-/- mice. 
Related to Figure 5.
IL-17A-producing cells were evaluated by flow cytometric analysis after epicutaneous S. 
aureus colonization in WT mice and Tcrd-/- mice treated with controlAb and anti-CD90Ab. 
Representative flow cytometric analysis of lineage (B220, CD11b, CD11c, Gr-1, NK1.1)-
negative cells and gd T cells was performed on gated CD45+CD90+IL-17A+ skin cells (left 
panels) on day 7. Results in right panels represent mean ± SD of 3 experiments. The number 
of IL-17A+ cells in WT and Tcrd-/- mice (right panels). *P<0.05, **P<0.01, by one-way ANOVA 
test with Bonferroni’s correction.
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Figure S5. S. aureus PSMα, but not PSMb, peptides induce cell death of murine 
keratinocytes and mediate skin inflammation. Related to Figure 6.
A-B, IL-1a release (A) and cytotoxicity (B) of murine primary KCs from WT mice stimulated 
with culture supernatant of LAC WT, LAC ∆psma, or LAC ∆psmb. Data are representative of 3 
independent experiments. C, Representative macroscopic images of WT mice colonized with 
LAC WT, LAC ∆psma, or LAC ∆psmb on day 7 after colonization. D-E, Skin disease scores 
(D) and S. aureus CFU in the skin (E) of infected mice. Each dot represents an individual 
mouse. F-G, IL-1a release (F) and cytotoxicity (G) of murine primary KCs from WT mice 
stimulated with culture supernatant of ∆psma S. aureus reconstituted with psma plasmid 
(LAC ∆psma pTXΔa) or vector (LAC ∆psma pTXΔ16). Data are presented as mean ± SD (A, 
B, F, G). Data are combined of 2 independent experiments. n.s.; not significant, *P<0.05 and 
**P<0.01 by one-way ANOVA test with Bonferroni’s correction (A, B), Kruskal-Wallis test (D, 
E) or unpaired two-tailed Mann-Whitney U test (F, G).
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Figure S6. S. aureus PSMa peptides induce IL-1a release from human keratinocytes. 
Related to Figure 6.
A-B, IL-1a release (A) and cytotoxicity (B) of human primary KCs stimulated with culture 
supernatant of LAC WT, LAC ∆psma, or LAC ∆psmb. Data are representative of 3 
independent experiments. C-D, IL-1a release (C) and cytotoxicity (D) of human primary KCs 
stimulated with culture supernatant of ∆psma S. aureus reconstituted with psma plasmid
(LAC ∆psma pTXΔa) or its vector (LAC ∆psma pTXΔ16). Data are representative of 2 
independent experiments. E-F, IL-1a release (E) and cytotoxicity (F) of human primary KCs 
stimulated with synthetic formylated PSMa3 (fPSMa3). Data are representative of 2 
independent experiments. G-H, IL-1a release (G), and cytotoxicity (H) of human primary KCs 
stimulated with formylated PSMa3 in the presence and absence of IL-1 receptor antagonist, 
anakinra. Data are presented as mean ± SD. Data are representative of 2 independent 
experiments. n.s.; not significant, *P<0.05; **P<0.01, by Kruskal-Wallis test (A, B) or unpaired 
two-tailed Mann-Whitney U test (C-H).
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